OnKure Therapeutics, Inc. (OKUR)
OnKure Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boulder, CO, US. The stock last traded at $2.70, down 2.17% on the session, giving a market capitalisation of $109.4M. On trailing twelve-month figures it carries a trailing P/E of -0.97, a net margin of 0.0%. Its beta of 0.30 implies it has historically moved less than the broad market.
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
OnKure Therapeutics, Inc. is most often compared with the following Healthcare names: